{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:27:07Z","timestamp":1784856427341,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03467-2","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T08:03:13Z","timestamp":1730448193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2052-439X","authenticated-orcid":false,"given":"Anan S.","family":"Jarab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-7572","authenticated-orcid":false,"given":"Walid A.","family":"Al-Qerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8725-1993","authenticated-orcid":false,"given":"Lina M.","family":"Khdour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0209-3050","authenticated-orcid":false,"given":"Yousef A.","family":"Mimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-7922","authenticated-orcid":false,"given":"Maher R.","family":"Khdour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"3467_CR1","doi-asserted-by":"crossref","unstructured":"Nguyen K, Hignett E, Khachemoune A (2020) Current and emerging treatment options for metastatic melanoma: a focused review. Dermatology online journal 26(7)","DOI":"10.5070\/D3267049551"},{"issue":"2","key":"3467_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jaad.2021.03.109","volume":"85","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Knabel P, Fleischer AB Jr (2021) United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol 85(2):388\u2013395","journal-title":"J Am Acad Dermatol"},{"key":"3467_CR3","unstructured":"TERAS M (2020) Melanoma Markers and New Treatment Perspectives"},{"key":"3467_CR4","doi-asserted-by":"publisher","first-page":"108200","DOI":"10.1016\/j.pharmthera.2022.108200","volume":"239","author":"S Caksa","year":"2022","unstructured":"Caksa S, Baqai U, Aplin AE (2022) The future of targeted kinase inhibitors in melanoma. Pharmacol Ther 239:108200","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3467_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C (2021) Signal pathways of melanoma and targeted therapy. Signal Transduct Target Therapy 6(1):424","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"3467_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cancers12020482","volume":"12","author":"H Patel","year":"2020","unstructured":"Patel H et al (2020) Current advances in the treatment of BRAF-mutant melanoma. Cancers 12(2):482","journal-title":"Cancers"},{"key":"3467_CR7","doi-asserted-by":"crossref","unstructured":"Torres-Collado AX, Knott J, Jazirehi AR (2018) Reversal of resistance in targeted therapy of metastatic melanoma: Lessons learned from Vemurafenib (BRAFV600E-specific inhibitor). Cancers 10(6):157","DOI":"10.3390\/cancers10060157"},{"issue":"1","key":"3467_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/med.21404","volume":"37","author":"A Millet","year":"2017","unstructured":"Millet A et al (2017) Metastatic melanoma: insights into the evolution of the treatments and future challenges. Med Res Rev 37(1):98\u2013148","journal-title":"Med Res Rev"},{"key":"3467_CR9","doi-asserted-by":"publisher","first-page":"661737","DOI":"10.3389\/fimmu.2021.661737","volume":"12","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ et al (2021) Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Front Immunol 12:661737","journal-title":"Front Immunol"},{"issue":"19","key":"3467_CR10","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-16-0249","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A et al (2016) Increases in absolute lymphocytes and circulating CD4\u2009+\u2009and CD8\u2009+\u2009T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res 22(19):4848\u20134858","journal-title":"Clin Cancer Res"},{"key":"3467_CR11","doi-asserted-by":"crossref","unstructured":"Friedman CF et al (2022) Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer 10(1)","DOI":"10.1136\/jitc-2021-003853"},{"issue":"8","key":"3467_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ et al (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Reviews Clin Oncol 14(8):463\u2013482","journal-title":"Nat Reviews Clin Oncol"},{"key":"3467_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.critrevonc.2015.12.002","volume":"99","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Liu W, Gotlieb V (2016) The rapidly evolving therapies for advanced melanoma\u2014towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol\/Hematol 99:91\u201399","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"3467_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11523-021-00840-3","volume":"16","author":"H Stege","year":"2021","unstructured":"Stege H et al (2021) The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges. Target Oncol 16(5):537\u2013552","journal-title":"Target Oncol"},{"issue":"7","key":"3467_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/1346-8138.12873","volume":"42","author":"N Yamazaki","year":"2015","unstructured":"Yamazaki N et al (2015) Phase I\/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAFV 600 mutations. J Dermatol 42(7):661\u2013666","journal-title":"J Dermatol"},{"issue":"4","key":"3467_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin J et al (2014) Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15(4):436\u2013444","journal-title":"Lancet Oncol"},{"issue":"3","key":"3467_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA et al (2014) Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15(3):323\u2013332","journal-title":"Lancet Oncol"},{"issue":"9","key":"3467_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA et al (2016) Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17(9):1248\u20131260","journal-title":"Lancet Oncol"},{"issue":"21","key":"3467_CR19","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/cncr.29586","volume":"121","author":"AM Menzies","year":"2015","unstructured":"Menzies AM et al (2015) Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121(21):3826\u20133835","journal-title":"Cancer"},{"issue":"13","key":"3467_CR20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ et al (2015) Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 16(13):1389\u20131398","journal-title":"Lancet Oncol"},{"key":"3467_CR21","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2165\/11640870-000000000-00000","volume":"72","author":"A Sharma","year":"2012","unstructured":"Sharma A et al (2012) Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs 72:2207\u20132222","journal-title":"Drugs"},{"issue":"5","key":"3467_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1470-2045(18)30940-9","volume":"20","author":"D Schadendorf","year":"2019","unstructured":"Schadendorf D et al (2019) Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 20(5):701\u2013710","journal-title":"Lancet Oncol"},{"issue":"1","key":"3467_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/1078-0432.CCR-18-4180","volume":"26","author":"A Ribas","year":"2020","unstructured":"Ribas A et al (2020) Extended 5-year follow-up results of a phase ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res 26(1):46\u201353","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3467_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ced.13751","volume":"44","author":"P Chen","year":"2019","unstructured":"Chen P, Chen F, Zhou B (2019) Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Clin Exp Dermatol 44(3):243\u2013251","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"3467_CR25","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L et al (2015) Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE 10(3):e0118564","journal-title":"PLoS ONE"},{"issue":"3","key":"3467_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1001\/jamaoncol.2016.4877","volume":"3","author":"T Devji","year":"2017","unstructured":"Devji T et al (2017) Systemic therapy for previously untreated advanced BRAF-mutated melanoma: a systematic review and network meta-analysis of randomized clinical trials. JAMA Oncol 3(3):366\u2013373","journal-title":"JAMA Oncol"},{"key":"3467_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2020.04.044","volume":"135","author":"L Si","year":"2020","unstructured":"Si L et al (2020) Open-label, phase IIa study of dabrafenib plus trametinib in east Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer 135:31\u201338","journal-title":"Eur J Cancer"},{"issue":"5","key":"3467_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/jdv.16074","volume":"34","author":"C Longo","year":"2020","unstructured":"Longo C et al (2020) Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. J Eur Acad Dermatol Venereol 34(5):956\u2013966","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3467_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.11.001","volume":"357","author":"MF Simoes","year":"2015","unstructured":"Simoes MF, Sousa JS, Pais AC (2015) Skin cancer and new treatment perspectives: a review. Cancer Lett 357(1):8\u201342","journal-title":"Cancer Lett"},{"issue":"9","key":"3467_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","volume":"11","author":"A Kim","year":"2016","unstructured":"Kim A, Cohen MS (2016) The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin Drug Discov 11(9):907\u2013916","journal-title":"Expert Opin Drug Discov"},{"key":"3467_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","volume":"125","author":"A Hauschild","year":"2020","unstructured":"Hauschild A et al (2020) Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials. Eur J Cancer 125:114\u2013120","journal-title":"Eur J Cancer"},{"issue":"1","key":"3467_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/14740338.2018.1390562","volume":"17","author":"S Knispel","year":"2018","unstructured":"Knispel S et al (2018) The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. Exp Opin Drug Saf 17(1):73\u201387","journal-title":"Exp Opin Drug Saf"},{"key":"3467_CR33","doi-asserted-by":"crossref","unstructured":"Banzi M et al (2016) Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. OncoTargets and therapy 2725\u20132733","DOI":"10.2147\/OTT.S75104"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03467-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T16:07:58Z","timestamp":1732205278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03467-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3467"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03467-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"735"}}